Chirag Paswan says India working with global bodies on nutraceutical regulations

New Delhi: India is working with global regulatory bodies, like Codex Alimentarius Commission, to formulate regulations for the nutraceutical industry, which has huge growth potential, Food Processing Industries Minister Chirag Paswan said on Tuesday.

“Nutraceuticals are again one of the fastest-growing industries. When it comes to this particular sector, we need to have regulations in place,” Paswan told reporters on the sidelines of an Assocham event.

“We are working closely with international regulatory bodies like Codex to have formal regulations so that the industry can grow.”

The scope of this industry is massive, and since it is new, numerous reforms and policies need to be implemented, for which the government is currently in the process, he added.

Paswan, addressing the event, noted that the government is ready to address the gaps in the sector and urged stakeholders to suggest policy reforms.

He said the government is focusing on nutritional security, alongside food security.

India’s nutraceutical industry is experiencing rapid growth, fuelled by rising health awareness and preventive healthcare trends.

Nutraceuticals fall primarily under the Food Safety and Standards Authority of India (FSSAI) via the Food Safety and Standards Act, 2006. Core rules include FSS (Health Supplements, Nutraceuticals, etc.) Regulations, 2016, covering licensing, labelling, advertising claims, and contaminants.

Food business operators need FSSAI licenses for manufacturing and sales. Labelling must detail purpose, target groups, usage instructions, and precautions; no genetically modified ingredients are permitted currently.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’